Filing Details
- Accession Number:
- 0000950170-24-087435
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-29 18:37:35
- Reporting Period:
- 2024-07-25
- Accepted Time:
- 2024-07-29 18:37:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1812364 | Relay Therapeutics Inc. | RLAY | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1816210 | Sanjiv Patel | C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-25 | 50,000 | $5.04 | 816,130 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-25 | 50,000 | $9.16 | 766,130 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-07-26 | 36,706 | $5.04 | 802,836 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-26 | 36,706 | $9.07 | 766,130 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-07-25 | 50,000 | $0.00 | 50,000 | $5.04 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-07-26 | 36,706 | $0.00 | 36,706 | $5.04 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 518,779 | 2029-04-22 | No | 4 | M | Direct | |
| 482,073 | 2029-04-22 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 674,548 | Indirect | By The Patel Family Irrevocable Trust of 2019 |
| Common Stock | 687,355 | Indirect | By The SSP Irrevocable Trust of 2020 |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024.
- Includes 762,360 shares underlying restricted stock units.
- This transaction was executed in multiple trades at prices ranging from $9.00 to $9.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades at prices ranging from $9.00 to $9.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- The shares underlying this option vested in sixteen (16) equal quarterly installments after April 23, 2019.
Billionaire Hedge Funds
